| Archan Shah, MD, MRCP | |
|
2025 Morse Avenue, Pulmonary Medicine, Sacramento, CA 95825 | |
| (916) 973-4842 | |
| (916) 973-5828 |
| Full Name | Archan Shah |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 29 Years |
| Location | 2025 Morse Avenue, Sacramento, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346458254 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | A117223 (California) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | A117223 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Gateway Medical Center | Gilbert, AZ | Hospital |
| Banner Boswell Medical Center | Sun city, AZ | Hospital |
| Banner - University Medical Center Phoenix | Phoenix, AZ | Hospital |
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner Hospital Based Physicians Arizona Llc | 3274782487 | 398 |
| Banner Cancer Center Specialists Llc | 6103097779 | 266 |
News Archive
A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.
Women who reported eating diets rich in oils containing alpha-linolenic acid (ALA) seemed to have a lower risk of dying from heart disease and sudden cardiac death than women whose diets are low in the plant-derived fatty acid, researchers reported at the American Heart Association's Scientific Sessions 2004.
Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients.
CMS has ordered private insurers to payment of "'referral fees' to sales agents who steer a beneficiary to a company for enrollment," Florida Health News reports.
Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.
› Verified 5 days ago
| Entity Name | Banner Cancer Center Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518253152 PECOS PAC ID: 6103097779 Enrollment ID: O20110913000224 |
News Archive
A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.
Women who reported eating diets rich in oils containing alpha-linolenic acid (ALA) seemed to have a lower risk of dying from heart disease and sudden cardiac death than women whose diets are low in the plant-derived fatty acid, researchers reported at the American Heart Association's Scientific Sessions 2004.
Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients.
CMS has ordered private insurers to payment of "'referral fees' to sales agents who steer a beneficiary to a company for enrollment," Florida Health News reports.
Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.
› Verified 5 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.
Women who reported eating diets rich in oils containing alpha-linolenic acid (ALA) seemed to have a lower risk of dying from heart disease and sudden cardiac death than women whose diets are low in the plant-derived fatty acid, researchers reported at the American Heart Association's Scientific Sessions 2004.
Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients.
CMS has ordered private insurers to payment of "'referral fees' to sales agents who steer a beneficiary to a company for enrollment," Florida Health News reports.
Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Archan Shah, MD, MRCP 2025 Morse Avenue, Pulmonary Medicine, Sacramento, CA 95825 Ph: (916) 973-4842 | Archan Shah, MD, MRCP 2025 Morse Avenue, Pulmonary Medicine, Sacramento, CA 95825 Ph: (916) 973-4842 |
News Archive
A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada's special access program, this was only the third time this new type of ICD had been implanted in Canada.
Women who reported eating diets rich in oils containing alpha-linolenic acid (ALA) seemed to have a lower risk of dying from heart disease and sudden cardiac death than women whose diets are low in the plant-derived fatty acid, researchers reported at the American Heart Association's Scientific Sessions 2004.
Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients.
CMS has ordered private insurers to payment of "'referral fees' to sales agents who steer a beneficiary to a company for enrollment," Florida Health News reports.
Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.
› Verified 5 days ago
Vinod Trivedi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1508 Alhambra Blvd Ste 200, Sacramento, CA 95816 Phone: 916-325-1040 Fax: 916-669-4100 | |
Patrick Richards, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3000 Q St, Sacramento, CA 95816 Phone: 916-733-3346 Fax: 916-733-3320 | |
Betty Carolyn Murray, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3000 Q St Fl 3, Sacramento, CA 95816 Phone: 916-733-3400 Fax: 916-733-5384 | |
Stephanie T Le, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3301 C St Ste 1400, Sacramento, CA 95816 Phone: 916-734-6111 Fax: 916-731-7183 | |
Kathryn D Newell, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4860 Y St, Suite 0101, Sacramento, CA 95817 Phone: 916-734-4843 Fax: 916-734-2732 | |
Dr. Michael John Thornton, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4150 V St, Suite 3400, Sacramento, CA 95817 Phone: 916-734-3566 | |
Dr. Pouria Kashkouli, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4150 V St, #3116, Sacramento, CA 95817 Phone: 916-734-7080 |